症状可预测稳定性冠心病PCI的安慰剂对照疗效
ORBITA-2二次分析评估稳定性冠心病患者症状严重程度与性质同疾病严重程度的关系,以及症状对PCI安慰剂对照疗效的预测能力。结果显示症状与疾病严重程度关联弱,但Rose心绞痛和典型心绞痛症状可强预测PCI疗效。
要点
- 症状严重程度与解剖或缺血严重程度关联弱。
- Rose心绞痛和典型心绞痛是PCI疗效的强预测因子。
- 症状性质有助于筛选PCI获益患者。
核心结论
- 症状严重程度和性质与疾病严重程度关联弱,但症状性质强预测PCI的安慰剂对照疗效。
研究设计与样本
- ORBITA-2二次分析,评估随机前症状严重程度和性质与疾病严重程度的关系,并分析症状对PCI安慰剂对照疗效的预测能力。
主要发现
- 随机前每日心绞痛发作中位数0.8次(Q1-Q3: 0.4-1.6),64%有Rose心绞痛。
- 定量冠状动脉造影直径狭窄61%(Q1-Q3: 49%-74%),负荷超声评分1.0(Q1-Q3: 0.0-2.7),FFR 0.63(Q1-Q3: 0.49-0.75),iFR 0.78(Q1-Q3: 0.55-0.87)。
- 心绞痛症状评分与QCA序相关系数0.06(95% CrI: 0.00-0.08),与负荷超声0.09(95% CrI: 0.02-0.10),与FFR 0.04(95% CrI: -0.03 to 0.07),与iFR 0.04(95% CrI: -0.01 to 0.07)。
- Rose心绞痛预测PCI疗效OR: 1.9(95% CrI: 1.6-2.1; PrInteraction=99.9%),典型心绞痛OR: 1.8(95% CrI: 1.6-2.1; PrInteraction=99.9%)。
临床怎么用
- 临床中应关注心绞痛症状性质(如Rose心绞痛或典型心绞痛)以预测PCI获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Placebo-controlled evidence from ORBITA-2 (Objective Randomised Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina-2) found that percutaneous coronary intervention (PCI) in stable coronary artery disease with little or no antianginal medication relieved angina, but residual symptoms persisted in many patients. The reason for this was unclear. OBJECTIVES: This ORBITA-2 secondary analysis investigates the relationship between presenting symptoms and disease severity (anatomic, noninvasive, and invasive ischemia) and the ability of symptoms to predict the placebo-controlled efficacy of PCI. METHODS: Prerandomization symptom severity and nature were assessed using the ORBITA smartphone application and symptom and quality of life questionnaires including the World Health Organization Rose angina questionnaire (Rose). Disease severity was assessed using quantitative coronary angiography, stress echocardiography, fractional flow reserve, and instantaneous wave-free ratio. Bayesian ordinal regression was used. RESULTS: At prerandomization, the median number of daily angina episodes was 0.8 (Q1-Q3: 0.4-1.6), 64% had Rose angina, quantitative coronary angiography diameter stenosis was 61% (Q1-Q3: 49%-74%), stress echocardiography score was 1.0 (Q1-Q3: 0.0-2.7), fractional flow reserve was 0.63 (Q1-Q3: 0.49-0.75), and instantaneous wave-free ratio was 0.78 (Q1-Q3: 0.55-0.87). There was little relationship between symptom severity and nature and disease severity: angina symptom score with quantitative coronary angiography ordinal correlation coefficient: 0.06 (95% credible interval [CrI]: 0.00-0.08); stress echocardiography: 0.09 (95% CrI: 0.02-0.10); fractional flow reserve: 0.04 (95% CrI: -0.03 to 0.07); and instantaneous wave-free ratio: 0.04 (95% CrI: -0.01 to 0.07). However, Rose angina and guideline-based typical angina were strong predictors of placebo-controlled PCI efficacy (angina symptom score: OR: 1.9; 95% CrI: 1.6-2.1; probability of interaction [PrInteraction] = 99.9%; and OR: 1.8; 95% CrI: 1.6-2.1; PrInteraction = 99.9%, respectively). CONCLUSIONS: Although symptom severity and nature were poorly associated with disease severity, the nature of symptoms powerfully predicted the placebo-controlled efficacy of PCI.
引用
- Simader FA, Rajkumar CA, Foley MJ, et al. Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease. J Am Coll Cardiol. 2024. PMID: 38759906. doi:10.1016/j.jacc.2024.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。